Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis : An observational longitudinal study
Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato..
Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs.
Clinical trial identifier: NCT04673240.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in neurology - 14(2023) vom: 23., Seite 1133390 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baricich, Alessio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Botulinum toxin |
|---|
| Anmerkungen: |
Date Revised 25.04.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT04673240 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fneur.2023.1133390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355946920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355946920 | ||
| 003 | DE-627 | ||
| 005 | 20231226065425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fneur.2023.1133390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355946920 | ||
| 035 | |a (NLM)37090974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baricich, Alessio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis |b An observational longitudinal study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04673240 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato. | ||
| 520 | |a Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs | ||
| 520 | |a Clinical trial identifier: NCT04673240 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a botulinum toxin | |
| 650 | 4 | |a movement disorders | |
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a rehabilitation | |
| 650 | 4 | |a spasticity | |
| 650 | 4 | |a spinal cord injury | |
| 650 | 4 | |a traumatic brain injury | |
| 700 | 1 | |a Battaglia, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cuneo, Daria |e verfasserin |4 aut | |
| 700 | 1 | |a Cosenza, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Millevolte, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Cosma, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Filippetti, Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a Dalise, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Azzollini, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Chisari, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Spina, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Cinone, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Invernizzi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Paolucci, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Picelli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Santamato, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in neurology |d 2010 |g 14(2023) vom: 23., Seite 1133390 |w (DE-627)NLM204500133 |x 1664-2295 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:23 |g pages:1133390 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fneur.2023.1133390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 23 |h 1133390 | ||